Endoluminal Sciences is a Sydney, Australia-based, venture capital-backed company committed to the development of novel, platform technologies to dramatically enhance the clinical performance of endovascular prostheses. While its novel technologies are foreseen to have applications in a range of vascular disease states, the immediate focus is the transcatheter treatment of structural heart disease. The company is financed by GBS Venture Partners, Australia's leading healthcare venture capital firm, and Reidsdale Investments.
| Website | http://endoluminalsciences.com |
| Revenue | $5 million |
| Employees | 5 (2 on RocketReach) |
| Founded | 2007 |
| Address | Ste 145, National Innovation Centre, Australian Technology Park, 4 Cornwallis St, Eveleigh, Sydney, New South Wales 2015, AU |
| Phone | +61 2 9209 4213 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+7 more
(view full list)
|
| Industry | Medical Devices & Equipment, Biotechnology, Other Healthcare Technology Systems, Manufacturing, Science and Engineering, Other Pharmaceuticals and Biotechnology, Health Care, Wellness |
| Keywords | Stents, Endovascular Devices, Medical Devices, Medical Technology, Vascular Grafts, Vascular Surgery, Platform Technology, Surgical Devices, Catheters, Healthcare Technology, Interventional Cardiology, Minimally Invasive Surgery, Angioplasty, Medical Innovation, Clinical Performance, Biomedical Engineering, Drug Delivery, Venture Capital |
| SIC | SIC Code 384 Companies, SIC Code 38 Companies |
| NAICS | NAICS Code 33 Companies, NAICS Code 339 Companies |
Looking for a particular Endoluminal Sciences Pty Ltd employee's phone or email?
The Endoluminal Sciences Pty Ltd annual revenue was $5 million in 2026.
Martin Ng is the Founder and Chief Medical Officer of Endoluminal Sciences Pty Ltd.
2 people are employed at Endoluminal Sciences Pty Ltd.
Endoluminal Sciences Pty Ltd is based in Sydney, New South Wales.
The NAICS codes for Endoluminal Sciences Pty Ltd are [33, 339].
The SIC codes for Endoluminal Sciences Pty Ltd are [384, 38].